Atea Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 75
- Market Cap
- $324.1M
- Website
- http://www.ateapharma.com
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin
Phase 1
Recruiting
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: Digoxin vs Digoxin + BEM/RZR vs Digoxin + 2h BEM/RZRDrug: Rosuvastatin vs Rosuvastatin + BEM/RZR vs Rosuvastatin + 2h BEM/RZR
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06921941
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Canada
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Phase 1
Not yet recruiting
- Conditions
- Healthy Volunteer StudyHepatic ImpairmentRenal Impairment
- Interventions
- Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06911320
- Locations
- 🇺🇸
Atea Study Site, Tampa, Florida, United States
C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
Phase 3
Recruiting
- Conditions
- HEPATITIS C VIRUS CHRONIC INFECTION
- Interventions
- Drug: Bemnifosbuvir-Ruzasvir (BEM/RZR)Drug: Sofosbuvir-Velpatasvir (SOF/VEL)
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 880
- Registration Number
- NCT06868264
- Locations
- 🇺🇸
Atea Study Site, Seattle, Washington, United States
Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT06356194
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Canada
Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
Phase 1
Recruiting
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditionsDrug: Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditionsDrug: Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06204679
- Locations
- 🇺🇸
Atea Study Site, Cypress, California, United States
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic HCV
Phase 2
Completed
- Conditions
- Chronic Hepatitis C VirusHepatitis CHepatitis C, ChronicHepatic CirrhosisHCV
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 275
- Registration Number
- NCT05904470
- Locations
- 🇹🇷
Atea Study Site, Kayseri, Turkey
The Study of Bemnifosbuvir in Healthy Japanese Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: Bemnifosbuvir (BEM)
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05905497
- Locations
- 🇺🇸
Atea Study Site, Cypress, California, United States
Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05905484
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir
Phase 1
Completed
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: Cohort 1 BEM + RuzasvirDrug: Cohort 2 Ruzasvir + BEM
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05731843
- Locations
- 🇨🇦
Atea Study Site, Québec, Montreal, Quebec, Canada
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
Phase 1
Completed
- Conditions
- Healthy VolunteerHepatic Impairment
- Interventions
- Drug: Bemnifosbuvir (BEM)
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Atea Pharmaceuticals, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05724693
- Locations
- 🇺🇸
Atea Study Site Orlando Clinical Research Center, Orlando, Florida, United States
© Copyright 2025. All Rights Reserved by MedPath